Celine R. M. van Latum

Celine R. M. van Latum

Auto-generated profile, based on publicly available information

Celine R. M. van Latum

Department of Intensive Care Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 August 2021 in Critical Care
Verified
Journal Article
Open access
PDF file
EKEmma J. Kooistra
Emma J. Kooistra
MBMiranda van Berkel
Miranda van Berkel
NKNoortje F. van Kempen
Noortje F. van Kempen
CLCeline R. M. van Latum
Celine R. M. van Latum
NBNiklas Bruse
Niklas Bruse
PPPeter Pickkers
Peter Pickkers
Background: Procalcitonin (PCT) and C-reactive protein (CRP) were previously shown to have value for the detection of secondary infections in critically ill COVID-19 patients. However, since the introduction of immunomodulatory therapy, the value of these biomarkers is unclear. We investigated PCT and CRP kinetics in critically ill COVID-19 patients treated with dexamethasone with or without tocilizumab, and assessed the value of these biomarkers to detect secondary bacterial infections.Methods: In this prospective study, 190 critically ill COVID-19 patients were divided into three treatment groups:no dexamethasone, no tocilizumab (D−T−),dexamethasone, no tocilizumab (D+T−), anddexamethasone and tocilizumab (D+T+). Serial data of PCT and CRP were aligned on the last day of dexamethasone treatment, and kinetics of these biomarkers were analyzed between 6 days prior to cessation of dexamethasone and 10 days afterwards. Furthermore, the D+T− and D+T+ groups were subdivided into secondary infection and no-secondary infection groups to analyze differences in PCT and CRP kinetics and calculate detection accuracy of these biomarkers for the occurrence of a secondary infection.Results: Following cessation of dexamethasone, there was a rebound in PCT and CRP levels, most pronounced in the D+T− group. Upon occurrence of a secondary infection, no significant increase in PCT and CRP levels was observed in the D+T− group (p = 0.052 andp = 0.08, respectively). Although PCT levels increased significantly in patients of the D+T+ group who developed a secondary infection (p = 0.0003), this rise was only apparent from day 2 post-infection onwards. CRP levels remained suppressed in the D+T+ group. Receiver operating curve analysis of PCT and CRP levels yielded area under the curves of 0.52 and 0.55, respectively, which are both markedly lower than those found in the group of COVID-19 patients not treated with immunomodulatory drugs (0.80 and 0.76, respectively, withpvalues for differences between groups of 0.001 and 0.02, respectively).Conclusions: Cessation of dexamethasone in critically ill COVID-19 patients results in a rebound increase in PCT and CRP levels unrelated to the occurrence of secondary bacterial infections. Furthermore, immunomodulatory treatment with dexamethasone and tocilizumabconsiderably reducesthe value of PCT and CRP for detection of secondary infections in COVID-19 patients.

Verified
Journal Article
Open access
EKEmma J. Kooistra
Emma J. Kooistra
MBMiranda van Berkel
Miranda van Berkel
NKNoortje F. van Kempen
Noortje F. van Kempen
CLCeline R. M. van Latum
Celine R. M. van Latum
NBNiklas Bruse
Niklas Bruse
PPPeter Pickkers
Peter Pickkers
Additional file 2. Fig. S2: Levels of A) procalcitonin (PCT) and B) C-reactive protein (CRP) over time within 10 days prior to and 10 days following the day of secondary infection in all patients of the second cohort treated with dexamethasone with or without tocilizumab (D+T-/+ group) who developed a secondary infection early (≤4 days) and late (> 4 days) following cessation of dexamethasone. Day of secondary infection was designated day 0 (alignment day). Data are presented as geometric mean with 95% confidence intervals. P-values were calculated using mixed-models analyses (time*group interaction factor). P-values in left and right parts of each panel reflect between-group differences in kinetics from day -10 until day 0 and from day 0 until day 10, respectively. Colored diamonds reflect p-values of

Verified
Journal Article
Open access
EKEmma J. Kooistra
Emma J. Kooistra
MBMiranda van Berkel
Miranda van Berkel
NKNoortje F. van Kempen
Noortje F. van Kempen
CLCeline R. M. van Latum
Celine R. M. van Latum
NBNiklas Bruse
Niklas Bruse
PPPeter Pickkers
Peter Pickkers
Additional file 1. Fig. S1: Pie charts illustrating the sites of secondary bacterial infections and the causative pathogens in the second cohort (patients treated with dexamethasone with or without tocilizumab, D+T-/+ group).